Supriya Lifescience Ltd., a cGMP-compliant global API manufacturer with a presence in over 120 countries, has announced its unaudited financial results for the second quarter of FY26. The company, known for its diversified product portfolio across therapeutic segments such as anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic, delivered a robust performance with a 20.3% year-on-year revenue increase.
Key Consolidated Financial Highlights (₹ in crore)
| Particulars | Q2 FY26 | Q2 FY25 |
|---|---|---|
| Revenues | 199.83 | 166.10 |
| EBITDA | 72.65 | 64.72 |
| EBITDA Margin | 36.4% | 39.0% |
| PAT | 50.43 | 46.15 |
| PAT Margin | 25.2% | 27.8% |
| Quarterly EPS (₹) | 6.27 | 5.71 |
Performance Highlights
- Revenue Growth: Supriya Lifescience reported revenues of ₹199.83 crore in Q2 FY26, up 20.3% from ₹166.10 crore in Q2 FY25.
- Profitability: EBITDA stood at ₹72.65 crore with a margin of 36.4%, compared to ₹64.72 crore and a 39.0% margin last year. PAT rose to ₹50.43 crore from ₹46.15 crore, reflecting steady profitability.
- Segment Growth:
- The anaesthetic segment led revenue growth, contributing 54% to H1 FY26 revenues, up from 46% in H1 FY25.
- The anti-histamine segment share increased to 12% (from 10%), and the vitamin segment also grew to 12% (from 11%) during the same period.
Geographical Performance
European markets remained the company’s largest revenue driver, contributing 37% of total business in Q2 FY26. The Asian and Latin American (LATAM) markets also posted strong growth — Asia accounted for 34% (up from 32% in Q1 FY26), while LATAM contributed 21% (up from 17% in Q1 FY26).
Operational Update
Capacity utilization improved from 70% in FY25 to 78% in H1 FY26, driven by higher demand and operational ramp-up. The company has also acquired three new land parcels near its existing plants to support future expansion and business diversification.
Management Commentary
Satish Wagh, Executive Chairman and Whole-Time Director, said:
“Our second quarter reflects a healthy recovery in revenue and sustained profitability, supported by steady demand across key markets. Exports contributed around 81% of Q2 FY26 revenues, with Europe accounting for 40% of the total business mix.
Capacity utilization improved to 78% in H1 FY26, aided by the ramp-up of the newly commissioned Module E at our Lote Parshuram facility, enhancing operational efficiency and stability. With the upcoming commercial launch of our Ambernath formulation facility in H2 FY26 and continued focus on regulated markets, backward integration, and new product launches, we remain confident of delivering stronger growth in the second half of the year.”